Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen

Ryu, Il Hwan; Cho, In Sung; Ryu, Aeli; Kim, Min; Jeon, Jae Wan; Kim, Joo Seok; Lee, Jae Joon; Choi, Jin Woo; Kang, Dong Wook

doi:10.4143/crt.2013.122

Cited by 5 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many chemotherapy regimens result in acceptable CR (about 90% in previous studies), the long-term overall survival (OS) rate is still poor [5,6,11]. The 5-year disease-free survival of the patients with different intensive chemotherapy regimens is <40% [1,[12][13][14]. The relapse happens in the course of 1-3 months after CR.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience

et al. 2018

View full text Add to dashboard Cite

Several chemotherapy regimens have been developed for the treatment of acute lymphoblastic leukemia (ALL), but relapse still presents the most common obstacles to attaining long‐term survival. The hyper‐CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and prednisolone)/HD MTX and Ara‐C (high‐dose methotrexate and cytarabine) chemotherapy regimen was first started in the MD Anderson Cancer Center as an intensive regimen for adult patients with ALL. The purpose of this study was to evaluate the effectiveness of a modified hyper‐CVAD protocol. We used hyper‐CVAD as consolidation/maintenance after remission induction with daunorubicin, vincristine, and prednisolone (and cyclophosphamide for T‐cell ALL only) rather than standard hyper‐CVAD in order to reduce treatment complications. This study was conducted as a retrospective review of medical records of ALL patients at 501 army hospital, Tehran, Iran, from 2005 to 2015. Three hundred and one patients underwent modified hyper‐CVAD chemotherapy regimen. Complete remission and overall survival (OS) rates were measured as primary endpoints. Two hundred and forty‐six (81.7%) reached complete remission (CR) during the first 6 months of treatment, and 55 patients (18.3%) did not reach CR. The 5‐year OS rate was 51.8% (95% CI (confidence interval): 45.1–57.8%). Modified hyper‐CVAD regimen is an efficient intensive chemotherapy regimen for consolidation/maintenance of adults with newly diagnosed ALL and has an acceptable 5‐year overall that is comparable to standard hyper‐CVAD regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience

et al. 2018

View full text Add to dashboard Cite

show abstract

“…T-lymphoblastic lymphoma (T-LBL) is a neoplasm of immature T-cell lineage (T-LBL) T-LBL is more common in children than in adults and concerns mostly boys. The pathologic characteristics of LBL are similar to those of acute lymphoblastic leukemia (ALL), 90 The difference between acute lymphoblastic leukemia is that in LBL bone marrow involvement is below 25% (or 20% according to WHO). 91 Lately, after the adoption of pediatricderived, lymphoblastic leukemia-like protocols the survival in T-LBL has improved significantly.…”

Section: T-lymphoblastic Lymphomamentioning

confidence: 97%

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

Stefaniuk¹,

Szymczyk²,

Podhorecka³

2020

CMAR

View full text Add to dashboard Cite

Despite the presence of many hematological prognostic indexes, clinical course and overall survival are often highly variable even within the same patient subgroup. Recent studies suggest that simple, cost-effective, low-risk tests such as neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR) may be used to evaluate the prognosis. Their role has been well confirmed in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and multiple myeloma (MM), but until now the prognostic significance of NLR and LMR in leukemias has not been widely reported. In this article, we analyze the literature data on prognostic value of NLR and LMR in haematological malignancies in the context of classic prognostic factors and clinical course.

show abstract

“…3 The response rate to chemotherapy is very good although relapse is common with poor survival rates. 4,5…”

Section: Introductionmentioning

confidence: 99%

An aberrant presentation of non-hodgkin’s lymphoma as pus: A curious journey

Devraj¹,

Kappagantu²,

Dugad³

et al. 2023

IJIRM

View full text Add to dashboard Cite

T-lymphoblastic lymphoma (T-LBL) is most commonly found in younger age group and rare. It is most aggressive form ofnon-Hodgkin’s lymphoma. T-lymphoblastic lymphoma (T-LBL) response rate to chemotherapy is very good although relapse is common with poor survival rates.A 25 years old female presented to emergency department of a tertiary care centre with dyspnoea and chest tube in left Hemothorax in situ. She had earlier history of pulmonary tuberculosis 3 years back and took anti tubercular treatment for 6 months. On general examination we found left supraclavicular lymphadenopathy of size 2 × 1.5cm and grade 2 clubbing.The pleural fluid was sent for analysis. It was reported as exudative pleural effusion with low ADA and negative for malignant cells. Lymph node biopsy was sent for histopathological examination which was reported as T Lymphoblastic lymphoma. NHL is a diverse category of cancers that originate from B or T cells at different stages of maturation. In relation to our case; earlier history of tuberculosis, pus from lymph node could mislead to infective aetiology; as lymph node necrosis is commonly found in Hodgkin’s disease. This fact reiterates the fact that through clinical examination and history leads to proper diagnosis and management of the patient and can save time of the patients.

show abstract

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen

Cited by 5 publications

References 12 publications

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

An aberrant presentation of non-hodgkin’s lymphoma as pus: A curious journey

Contact Info

Product

Resources

About